Sodium valproate is a medication primarily used to treat epilepsy and bipolar disorder. However, it has also been linked to birth defects and developmental issues in babies born to women who took the drug during pregnancy. As a result, a recent sodium valproate agreement has been reached in the UK.
The agreement, announced on March 22nd 2021, is a formal response to the harm caused by sodium valproate, and outlines the steps that will be taken in order to provide support to those affected. The agreement includes the creation of a support scheme, funded by the manufacturers of the drug, to provide financial assistance to families affected by sodium valproate-related birth defects. The scheme will also provide access to specialist medical assessments and treatment.
The agreement also includes a commitment to improve information and advice provided to women who are prescribed sodium valproate. This includes the creation of a patient booklet, which will be given to all women prescribed the drug, and improved communication between healthcare professionals and their patients.
For those affected by sodium valproate, the agreement is a step in the right direction. It acknowledges the harm caused by the drug and provides concrete support for those affected. The support scheme is particularly significant, as it will provide financial assistance to families who may otherwise struggle to cover the costs of ongoing medical care and support.
However, some have criticised the agreement for not going far enough. The support scheme is only available to those affected by birth defects, and does not cover other harms caused by the drug, such as developmental issues or behavioural problems. Additionally, the agreement does not include any compensation for those affected, which has led some to call for legal action against the manufacturers of sodium valproate.
Overall, the sodium valproate agreement represents an important step towards providing support and assistance to those affected by the drug. While there is still more to be done to address the harm caused, the agreement is a positive development and represents a significant step forward in improving the care and support available to those affected by sodium valproate-related birth defects.